Rankings
▼
Calendar
BOLD
Boundless Bio, Inc.
$26M
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$1M
Operating Income
-$73M
Net Income
-$65M
EPS (Diluted)
$-3.85
Cash Flow
Operating Cash Flow
-$61M
Free Cash Flow
-$63M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$206M
Total Liabilities
$56M
Stockholders' Equity
$151M
Cash & Equivalents
$27M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
-$1M
$0
—
Operating Income
-$73M
-$55M
-33.7%
Net Income
-$65M
-$49M
-32.2%
← Q4 2023
All Quarters
Q1 2024 →
BOLD FY 2024 Earnings — Boundless Bio, Inc. Revenue & Financial Results | Market Cap Arena